Glaukos (NYSE:GKOS) Stock Price Expected to Rise, Needham & Company LLC Analyst Says

Key Points

• Needham raised Glaukos’ price target to $251 from $201 and maintained a “Buy” rating, implying 38.32% upside from the previous close. The stock has a consensus “Moderate Buy” rating and an average target of $190.36.
• Glaukos reported strong quarterly results, with revenue rising 58% year over year to $211.03 million and adjusted EPS of $0.47, far exceeding analysts’ expectations for a loss. Management also sharply increased full-year sales guidance and set a preliminary 2027 revenue target of approximately $1 billion.
• Valuation and insider activity remain risks: Shares are near their 52-week high while trailing profitability metrics remain negative, and insiders have sold more than 83,000 shares worth roughly $15 million over the past 90 days.

Glaukos (NYSE:GKOS - Get Free Report) had its price target raised by analysts at Needham & Company LLC from $201.00 to $251.00 in a research note issued to investors on Thursday, Marketbeat Ratings reports. The brokerage presently has a "buy" rating on the medical instruments supplier's stock. Needham & Company LLC's price objective points to a potential upside of 38.32% from the company's previous close.

Several other analysts also recently issued reports on GKOS. HC Wainwright upped their price objective on shares of Glaukos from $168.00 to $195.00 and gave the stock a "buy" rating in a report on Thursday, July 30th. Mizuho set a $225.00 target price on shares of Glaukos in a research report on Thursday. Truist Financial set a $255.00 target price on shares of Glaukos in a research report on Thursday. Stifel Nicolaus raised their price target on Glaukos from $175.00 to $190.00 and gave the company a "buy" rating in a research report on Thursday, July 30th. Finally, Weiss Ratings reiterated a "sell (d-)" rating on shares of Glaukos in a research note on Thursday, October 15th. Thirteen analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average target price of $190.36.

Glaukos Stock Performance

GKOS opened at $181.47 on Thursday. The company has a debt-to-equity ratio of 0.10, a quick ratio of 4.46 and a current ratio of 5.04. The company has a market cap of $10.70 billion, a PE ratio of -55.84 and a beta of 0.69. The stock has a 50-day moving average of $171.24 and a 200-day moving average of $139.87. Glaukos has a 52-week low of $76.88 and a 52-week high of $191.62.

Glaukos (NYSE:GKOS - Get Free Report) last announced its earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.10) by $0.57. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%. The firm had revenue of $211.03 million during the quarter, compared to analysts' expectations of $168.04 million. During the same quarter in the prior year, the business earned ($0.16) earnings per share. The company's revenue was up 58.0% on a year-over-year basis. As a group, equities research analysts forecast that Glaukos will post -0.32 earnings per share for the current fiscal year.

Insider Activity at Glaukos

In other news, Director Leana Wen sold 525 shares of the company's stock in a transaction dated Friday, July 31st. The shares were sold at an average price of $167.63, for a total transaction of $88,005.75. Following the completion of the transaction, the director owned 21,092 shares of the company's stock, valued at approximately $3,535,651.96. This represents a 2.43% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Joseph Gilliam sold 60,000 shares of the stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $179.74, for a total transaction of $10,784,400.00. Following the completion of the sale, the chief operating officer owned 72,588 shares of the company's stock, valued at approximately $13,046,967.12. The trade was a 45.25% decrease in their position. The disclosure for this sale is available in the SEC filing. Over the last 90 days, insiders have sold 83,025 shares of company stock valued at $14,950,006. Company insiders own 5.90% of the company's stock.

Hedge Funds Weigh In On Glaukos

Several large investors have recently added to or reduced their stakes in GKOS. State of Wyoming increased its position in shares of Glaukos by 6.8% during the 3rd quarter. State of Wyoming now owns 1,030 shares of the medical instruments supplier's stock worth $169,000 after purchasing an additional 66 shares in the last quarter. Wealth Alliance LLC lifted its holdings in Glaukos by 4.5% during the 1st quarter. Wealth Alliance LLC now owns 2,297 shares of the medical instruments supplier's stock valued at $247,000 after purchasing an additional 98 shares during the last quarter. Abel Hall LLC lifted its holdings in Glaukos by 3.5% during the 3rd quarter. Abel Hall LLC now owns 3,236 shares of the medical instruments supplier's stock valued at $531,000 after purchasing an additional 108 shares during the last quarter. Choreo LLC boosted its position in Glaukos by 4.0% in the third quarter. Choreo LLC now owns 3,546 shares of the medical instruments supplier's stock valued at $582,000 after buying an additional 136 shares in the last quarter. Finally, Farther Finance Advisors LLC boosted its position in Glaukos by 25.4% in the third quarter. Farther Finance Advisors LLC now owns 681 shares of the medical instruments supplier's stock valued at $112,000 after buying an additional 138 shares in the last quarter. Institutional investors and hedge funds own 99.04% of the company's stock.

Key Headlines Impacting Glaukos

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Record revenue beat expectations: Third-quarter revenue increased approximately 58% year over year to $211.0 million, exceeding the $168.0 million consensus estimate. Gross profit rose to $179.9 million. Glaukos Corporation Reports Third-Quarter Earnings
• Positive Sentiment: Profitability materially outperformed forecasts: Glaukos reported adjusted earnings of $0.47 per share, compared with analysts’ expected loss of approximately $0.10–$0.12 per share and a year-ago loss of $0.16. GAAP net income attributable to common shareholders was $2.0 million, or $0.03 per diluted share, marking a return to profitability. Glaukos Q3 Earnings and Revenue Results
• Positive Sentiment: Full-year guidance was sharply increased: Management raised 2026 net-sales guidance to $775 million–$785 million from $680 million–$700 million. It also introduced a preliminary 2027 sales target of approximately $1 billion, signaling confidence in sustained demand and product adoption. Glaukos Raises Sales Outlook
• Positive Sentiment: Cash generation remained solid: Operating activities generated $14.8 million, while Glaukos ended the quarter with $162.3 million in cash and cash equivalents and modest capital spending of $2.7 million.
• Neutral Sentiment: Investor expectations are elevated: The stock is near its 52-week high, while the reported P/E remains negative and the company continues to post negative trailing profitability metrics. Continued execution will be necessary to support the higher valuation.
• Negative Sentiment: Insider selling is a potential overhang: Company insiders reported 32 open-market sales and no purchases during the past six months. In addition, the median analyst price target cited in the provided reports was $165, below the current share-price range.

Glaukos Company Profile

Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company's principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.

Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, including the iStent family of implantable devices used to help lower intraocular pressure in patients with glaucoma.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.